Alyeska Investment Group
ARGS

Alyeska Investment Group’s Argos Therapeutics, Inc. ARGS Stock Holding History

Alyeska Investment Group’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-5,571
Closed -$521K – 620
2016
Q3 		$554K Buy
+5,571
New +$582K 0.01% 430
2016
Q1 		– Sell
-10,107
Closed -$467K – 523
2015
Q4 		$467K Buy
10,107
+2,906
+40% +$246K 0.01% 355
2015
Q3 		$694K Buy
7,201
+572
+9% +$67.8K 0.01% 408
2015
Q2 		$908K Sell
6,629
-1,223
-16% -$195K 0.01% 413
2015
Q1 		$1.4M Buy
7,852
+2,817
+56% +$490K 0.02% 409
2014
Q4 		$1.01M Buy
5,035
+1,063
+27% +$191K 0.02% 398
2014
Q3 		$799K Sell
3,972
-2,790
-41% -$436K 0.02% 342
2014
Q2 		$1.09M Buy
6,762
+1,033
+18% +$171K 0.02% 347
2014
Q1 		$1.15M Buy
+5,729
New +$1.15M 0.03% 291

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Alyeska Investment Group's ARGS Position: Q4 2016 in Review

Alyeska Investment Group sold out of Argos Therapeutics, Inc. (ARGS) in Q4 2016, closing a stake of 5,571 shares — an estimated $521K sold.

Alyeska Investment Group first reported a position in ARGS in Q1 2014 and held it in 9 quarters. The position peaked at $1.4M in Q1 2015. 52 funds tracked by Wall St. Rank hold ARGS as of Q4 2016.

  • Alyeska Investment Group reported no remaining Argos Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Alyeska Investment Group sold 5,571 Argos Therapeutics, Inc. shares in Q4 2016, an estimated $521K.
  • Alyeska Investment Group first reported a position in Argos Therapeutics, Inc. in Q1 2014 and held it in 9 quarters.
  • Alyeska Investment Group's Argos Therapeutics, Inc. position peaked at $1.4M in Q1 2015.
  • 52 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q4 2016.

Based on Alyeska Investment Group's 13F filing for Q4 2016, filed 14 Feb 2017.